ASCO GI: ASCO Gastrointestinal Cancers Symposium

Kohei Shitara, MD, discusses CLDN18.2-guided therapy, nivolumab plus zolbetuximab, and toxicity management in advanced gastric and gastroesophageal cancers.

New research presented at ASCO GI positions both agents as potent therapeutic options, with potential to redefine standard care for aggressive HER2-driven gastrointestinal cancers.

Presenters shared their personal highlights of attending ASCO GI 2026.

Dani Castillo, MD, sheds light on the evolving landscape of first-line therapy in advanced gastric cancer.

W. Kimryn Rathmell, MD, PhD, FASCO, champions the dyad model to enhance oncology care accessibility, bridging gaps between rural patients and clinical trials.

Michael David Chuong, MD, discusses how SBRT has become a leading option for treating patients with colorectal liver metastases.

Yuman Fong, MD, discusses the evolution of colorectal liver metastases management from historical neglect to multimodal approaches.

The complex disparities in pancreatic cancer survival trends across demographics and regions highlight urgent needs for targeted interventions.

Filippo Pietrantonio, MD, discusses findings from the phase 1/2 OrigAMI-1 study in RAS/BRAF wild-type mCRC.

Zanidatamab shows promise in extending survival for patients with HER2-positive biliary tract cancer, marking a significant breakthrough in treatment options.

Elena Elimova, MD, shares efficacy data for zanidatamab in patients with HER2-positive gastroesophageal adenocarcinoma from HERIZON-GEA-01.

Circulating tumor DNA shows promise in detecting esophageal cancer recurrence earlier than traditional methods, enhancing posttreatment surveillance.

Tobacco use significantly impacts gastric and esophageal cancer outcomes, highlighting the need for targeted public health strategies and smoking cessation efforts.

Enrique Velazquez Villarreal, MD, PhD, MPH, MS, reveals how AI is being used to identify early-onset CRC and enhance precision oncology.

The trial is investigating zanidatamab with/without tislelizumab plus chemotherapy in HER2-positive advanced or metastatic gastroesophageal adenocarcinoma.